Josep Carreras Leukemia Research Institute (IJC), Badalona, Barcelona, Catalonia, Spain; Centro de Investigación Biomédica en Red Cancer (CIBERONC), Madrid, Spain.
Josep Carreras Leukemia Research Institute (IJC), Badalona, Barcelona, Catalonia, Spain.
Trends Immunol. 2020 Aug;41(8):676-691. doi: 10.1016/j.it.2020.06.002. Epub 2020 Jul 2.
Effective anticancer immunotherapy treatments constitute a qualitative leap in cancer management. Nonetheless, not all patients benefit from such therapies because they fail to achieve complete responses, suffer frequent relapses, or develop potentially life-threatening toxicities. Epigenomic signatures in immune and cancer cells appear to be accurate and promising predictors of patient outcomes with immunotherapy. In addition, combined treatments with epigenetic drugs can exploit the dynamic nature of epigenetic changes to potentially modulate responses to immunotherapy. Candidate epigenetic biomarkers may provide a rationale for patient stratification and precision medicine, thus maximizing the chances of treatment success while minimizing unwanted effects. We present a comprehensive up-to-date view of potential epigenetic biomarkers in immunotherapy and discuss their advantages over other indicators.
有效的抗癌免疫治疗构成了癌症管理的质的飞跃。然而，并非所有患者都能从这些治疗中受益，因为他们无法实现完全缓解，经常复发，或产生潜在危及生命的毒性。免疫细胞和癌细胞中的表观基因组特征似乎是免疫治疗患者预后的准确且有前途的预测指标。此外，联合使用表观遗传药物可以利用表观遗传变化的动态性质，从而有可能调节对免疫治疗的反应。候选表观遗传生物标志物可为患者分层和精准医疗提供依据，从而最大限度地提高治疗成功的机会，同时最大限度地减少不良反应。我们全面介绍了免疫治疗中潜在的表观遗传生物标志物，并讨论了它们相对于其他指标的优势。
